projecteverest

[Proposed Experiment]: Health Malawi - Research Protocol Stage 3

by
Sunny Wu
+1
Submitted by
Sunny Wu | 2 weeks ago | in Health Consulting

Lean Phase: Solution

Assumption: Clinicians can correctly input symptoms verbally conveyed by patients during their consultation via USSD. 

Time frame: 4 months (ideally beginning of March to end of June, before commencement of July Trekker month) 

Success metric: 80% of USSD entries from patients have matching symptom entries from clinicians

Green light: Proceed to research protocol stage 4

Orange light point: 70% of USSD entries from patients have matching symptom entries from clinicians

Orange light: re-assess the user interface (UI) for clinician USSD system and consider conducting another training day for clinicians. 

Failure point: <70% of USSD entries from patients have matching symptom entries from clinicians

Red light: re-assess the user interface (UI) for clinician USSD system and consider conducting another training day for clinicians. 

 

Experiment Build

In order to develop a digital system that provides accurate and effective diagnoses for patients at home, patients’ ability to digitally convey their symptoms must be assessed. This was performed in RP2, however, in order to draw a more reliable conclusion, a much larger sample size is required. Thus, the primary purpose of RP3 is to allow for a more reliable analysis of patients’ ability to communicate symptoms using USSD by gathering a large quantity of data.

For patients, the methodology remains identical as RP2 – they are to input their symptoms digitally prior to their consultation with the clinician. Similar to RP2, patients will be able to access the digital survey without paying a fee. During the consultation, patients are to give the clinicians their previously assigned ID number.

RP3 is different to RP2 in that clinicians, instead of completing paper questionnaires, are asked to enter the symptoms verbally conveyed by patients via USSD on their mobile device. Clinicians must note that this step is to be carried out in conjunction with their current documentation processes and does not aim to replace these processes.

From February to July 2019, a goal of over 1000 patient data points with matching clinician samples will be collected and analysed. The analysis will provide a more reliable insight on patients’ ability to digitally convey their symptoms. Over the four-month period, Project Everest Ventures will follow-up on the progress of data collection for RP3 as well as assess engagement levels of USSD among participants through phone calls, emails and physical visits conducted by members of the research team. Gabriel Raubenheimer will be the primary contact through the email address: malawi@projecteverest.ventures, as well as on Whatsapp through the number: +61 449 663 775.

To help maintain the flow of data collection and hence achieving an ideal sample size, RP3 requires clinicians to encourage patients to participate in the digital survey before consultations. The research team will facilitate the process by distributing detailed instructions throughout the clinic to help patients access and complete the digital survey. In addition, an Australian point of contact will be provided. Overall, RP3 will be executed without any assistance from the research team as collection of survey data will be automated for both patients and clinicians.

 

No comments yet, be the first to post one!
Share